Fractyl raises series E funding of USD 55 million for diabetes cure

By Nikita Chaurasia  Date: 2020-08-10

Fractyl raises series E funding of USD 55 million for diabetes cure

Fractyl Laboratories raised series E funding of USD 55 million to continue financing the pivotal clinical trial of its potential non-surgical, non-drug treatment for Type 2 diabetes.

As per the trusted sources, the capital will be invested on mass-based startup’s Revita T2Di pivotal clinical trial of Revita DMR. Revita is observing the effect of Fractyl’s Revita DMR treatment on insulin requirements and glycemic control.

Reportedly, the funding round was led by the new investor named Taiwania Capital Management Corporation. The financing also involved the existing investors like Emergent Medical Partners, Bessemer Venture Partners, Domain Associates, True Ventures, General Catalyst, Mithril Capital Management, and GV. The funding round included first time commitments from CDIB Venture Capital Corp., Catalio Capital Management, and YJ Capital.

Michael Huang, managing partner at Taiwania Capital Management Corporation, has reportedly stated that type 2 diabetes and NAFLD/NASH have adverse effects on people’s health across the world and account for majority global healthcare expenditure. He further added that Fractyl has carried out studies which reveal Revita’s potential to enhance the outcomes of the treatment for type 2 diabetes.

Fractyl’s co-founder and CEO Harith Rajagopalan states that Fractyl’s mission is to treat diabetes type 2 in a better way by addressing its root cause, that can reverse the disease process rather than managing its symptoms. He said that they now have database of hundreds of patients who suffered from type 2 diabetes and have shown long term benefits of a single Revita treatment.

Rajagopalan added that he welcomes the new investors and the continued support of the returning investors who saw that they have the potential to redefine the treatment for metabolic diseases like NAFLD/NASH and type 2 diabetes.

The company is looking forward to beginning with their pivotal U.S. clinical trial later this year.

Source credits-

https://www.massdevice.com/fractyl-adds-55m-for-type-2-diabetes-pivotal-trial/

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

Razorpay: New funding en route, meteoric rise in market value expected
Razorpay: New funding en route, meteoric rise in market value expected
By Nikita Chaurasia

Indian startup Razorpay is reportedly in discussions with Singapore-based sovereign wealth fund GIC Pvt. Ltd. and other existing investors to raise around USD 200 million in a funding round that would allow the fintech company to double its valuation...

FDA to allow pharma companies modify COVID-19 shots amid variants surge
FDA to allow pharma companies modify COVID-19 shots amid variants surge
By Nikita Chaurasia

With the rising cases of Coronavirus variants, the United States Food & Drug Administration (FDA) has reportedly introduced guidelines for pharmaceutical companies to modify their COVID-19 vaccine doses in an effort to curb the spread of the dise...

Gan & Lee partners with IDF to expand its diabetes treatment portfolio
Gan & Lee partners with IDF to expand its diabetes treatment portfolio
By Nikita Chaurasia

China-based leading pharmaceutical organization Gan & Lee Pharmaceuticals Co. Ltd. has announced to have signed a strategic collaboration with the International Diabetes Federation (IDF) to bolster its efforts towards promoting the prevention and...

Google Pay under CCI investigation over antitrust claims in India
Google Pay under CCI investigation over antitrust claims in India
By Nikita Chaurasia

The Competition Commission of India (CCI) has reportedly begun an investigation to inspect if the renowned online payment system Google Pay has misused its dominance in the digital marketplace in the country. Sources close to the matter stated that ...

SpaceX’s valuation skyrockets with USD 850 million funding round
SpaceX’s valuation skyrockets with USD 850 million funding round
By Nikita Chaurasia

According to reliable sources, California-based aerospace manufacturer and space transportation services company SpaceX, headed by Tesla’s Chief Executive Elon Musk, recently completed an equity funding round of USD 850 million, post which the ...